PROTAC CRBN Degrader-1 is primarily used in targeted protein degradation, a cutting-edge approach in drug discovery and therapeutic development. It functions by recruiting E3 ubiquitin ligases, specifically CRBN, to tag unwanted or disease-causing proteins for degradation by the proteasome. This mechanism is particularly valuable in cancer research, where it can be used to degrade oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Additionally, it has potential applications in studying protein function and signaling pathways, offering insights into disease mechanisms and enabling the development of novel treatments for conditions like autoimmune disorders and neurodegenerative diseases. Its ability to selectively degrade proteins makes it a powerful tool in both preclinical research and therapeutic innovation.